{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:48:03Z","timestamp":1785754083498,"version":"3.56.0"},"reference-count":62,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01DA038886"],"award-info":[{"award-number":["U01DA038886"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01DA021525"],"award-info":[{"award-number":["U01DA021525"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SMN\u2010139148"],"award-info":[{"award-number":["SMN\u2010139148"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP\u2010286532"],"award-info":[{"award-number":["MOP\u2010286532"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SKF\u2010149507"],"award-info":[{"award-number":["SKF\u2010149507"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT\u2010175162"],"award-info":[{"award-number":["PJT\u2010175162"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Review"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Gabapentin is widely prescribed off\u2010label to treat pain. However, there are concerns about the proliferation of medical and non\u2010medical use, and the potential increased risk of overdose death associated with concurrent opioid use. Despite these considerations, prescription gabapentin use among people who use unregulated drugs is uncharacterised in Canada. Therefore, we investigated trends and factors associated with being prescribed gabapentin for pain among community\u2010recruited people who use opioids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were derived from three prospective cohort studies of people who use unregulated drugs in Vancouver, Canada, restricted to periods of opioid use (i.e., unregulated use, non\u2010medical use, and\/or opioid agonist treatment). We characterised factors associated with reporting gabapentin for pain between 2014 and 2020 using multivariable generalised estimating equations. Trends in self\u2010reported prescription (2014\u20132020) and non\u2010medical (2016\u20132024) gabapentin use were explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 2014 and 2020, we included 10,999 observations from 2039 participants who had a baseline median age of 38\u2009years and were 62.4% male and 57.5% White. Gabapentin prescriptions for pain were reported by 255 (12.5%) participants. Observations reporting a neuropathic pain diagnosis had 3.54 times the adjusted odds (95% CI 2.81, 4.46) of being prescribed gabapentin. From 2014 to 2020, the prevalence of gabapentin prescriptions rose from 5.4% to 7.8%. Non\u2010medical gabapentin use remained low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and Conclusions<\/jats:title>\n                    <jats:p>Among people who use opioids, we observed an increase in gabapentin prescriptions for pain between 2014 and 2020. Gabapentin prescriptions were strongly associated with reporting a neuropathic pain diagnosis. Rates of non\u2010medical gabapentin use were substantially lower than rates reported internationally.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dar.70186","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:09:26Z","timestamp":1781140166000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and Correlates of Reporting a Gabapentin Prescription for Pain Among People Who Use Opioids: A Longitudinal Community\u2010Recruited Study"],"prefix":"10.1111","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9569-4989","authenticated-orcid":false,"given":"Evelyne Marie","family":"Piret","sequence":"first","affiliation":[{"name":"School of Population and Public Health, University of British Columbia  Vancouver Canada"},{"name":"British Columbia Centre on Substance Use  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Palis","sequence":"additional","affiliation":[{"name":"School of Population and Public Health, University of British Columbia  Vancouver Canada"},{"name":"BC Centre for Disease Control  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Crabtree","sequence":"additional","affiliation":[{"name":"School of Population and Public Health, University of British Columbia  Vancouver Canada"},{"name":"BC Centre for Disease Control  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinCheol","family":"Choi","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kora","family":"DeBeck","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use  Vancouver Canada"},{"name":"School of Public Policy Simon Fraser University  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanna","family":"Hayashi","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use  Vancouver Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University  Burnaby Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Law","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences Cumming School of Medicine, University of Calgary  Calgary Canada"},{"name":"Centre for Health Policy, O'Brien Institute for Public Health University of Calgary  Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.\u2010J.","family":"Milloy","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use  Vancouver Canada"},{"name":"Division of Social Medicine, Department of Medicine University of British Columbia  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Pfizer Canada Inc \u201cProduct Monograph: Neurontin \u201d2018 Report No."},{"key":"e_1_2_11_3_1","unstructured":"Canadian Institute for Health Information \u201cPrescribed Drug Spending in Canada 2023: A Focus on Public Drug Programs\u2014Top 100 Drug Classes 2022 Data Tables \u201d2023 Report No."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010023\u201040637\u20108"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010083"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.202000338"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.3203"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1178221818801311"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.0086"},{"key":"e_1_2_11_10_1","unstructured":"US Food and Drug Administration \u201cPrescribing Information: Neurontin (Gabapentin) \u201d2017 Report No."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.7856"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS\u201025\u201001750"},{"key":"e_1_2_11_13_1","unstructured":"European Medicines Agency \u201cNeurontin \u2013 Referral [Internet] \u201dhttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/neurontin."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2022.01.006"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","unstructured":"J. W.Busse G. H.Guyatt A.Carrasco et\u00a0al. \u201cThe 2017 Canadian Guideline for Opioids for Chronic Non\u2010Cancer Pain \u201d2017 Report No.","DOI":"10.1503\/cmaj.733313"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/754693"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41393\u2010021\u201000744\u2010z"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(14)70251\u20100"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010022\u201001810\u20103"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3821\/145.6.cpj280"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010020\u201001432\u20107"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396"},{"key":"e_1_2_11_24_1","unstructured":"Health Canada \u201cInformation Update: Health Canada Advises Canadians to Exercise Caution When Taking Gabapentin or Pregabalin with Opioids \u201d2019 Report No."},{"key":"e_1_2_11_25_1","unstructured":"US Food and Drug Administration \u201cFDA in Brief: FDA Requires New Warnings for Gabapentinoids About Risk of Respiratory Depression \u201d2019 Report No."},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116028"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.3145"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002965"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16306"},{"key":"e_1_2_11_30_1","volume-title":"Opioid Agonist Therapy: A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder","author":"Centre for Addiction and Mental Health","year":"2021"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104123"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010020\u201000985\u20106"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477\u20107517\u20103\u201018"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.6.547"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199708000-00001"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889\u2010023\u201015929\u20109"},{"key":"e_1_2_11_37_1","unstructured":"Sanis Health Inc \u201cProduct Monograph: Pregabalin \u201d2017 Report No."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.2307\/2290467"},{"key":"e_1_2_11_40_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2022"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.09.019"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954\u2010024\u201000956\u20105"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263\u2010019\u201000660\u20100"},{"key":"e_1_2_11_44_1","unstructured":"British Columbia Centre on Substance Use BC Ministry of Health and BC Ministry of Mental Health and Addictions \u201cA Guideline for the Clinical Management of Opioid Use Disorder [Internet] \u201d2023 https:\/\/www.bccsu.ca\/opioid\u2010use\u2010disorder\/."},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380\u2010021\u201001386\u20106"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v9.i1.7"},{"key":"e_1_2_11_47_1","volume-title":"Treatment of Chronic Pain and Complex Concurrent Mental Health and Substance Use Conditions","author":"Best Brains Exchange","year":"2023"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109400"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11126\u2010016\u20109421\u20107"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2020.1817082"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12159"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12277"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.676224"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096\u2010020\u201001217\u20108"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13324"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.230715"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13690"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257025"},{"issue":"5","key":"e_1_2_11_59_1","first-page":"e277","article-title":"First\u2010Line Medications for Alcohol Use Disorders Among Public Drug Plan Beneficiaries in Ontario","volume":"63","author":"Spithoff S.","year":"2017","journal-title":"Canadian Family Physician"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.1271"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376\u20108716(98)00028\u20103"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1086\/269084"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2009.12.006"}],"container-title":["Drug and Alcohol Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.70186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dar.70186","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dar.70186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:20:54Z","timestamp":1785752454000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dar.70186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/dar.70186"],"URL":"https:\/\/doi.org\/10.1111\/dar.70186","archive":["Portico"],"relation":{},"ISSN":["0959-5236","1465-3362"],"issn-type":[{"value":"0959-5236","type":"print"},{"value":"1465-3362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"2026-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70186"}}